Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Feugier

Showing results (81-90 of 164) with videos related to

Pageof 17
Sort By:
Blood Cancer Journal|August 13, 2025
Genomic and immunogenomic profiling of extramedullary acute myeloid leukemia reveals actionable clonal branching and frequent immune editingClément Collignon, Tucker Hansen, Colin Hercus, et al.
American Journal of Hematology|October 22, 2017
Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO groupYann Guillermin, Charles Herbaux, Fabien Subtil, et al.
Hematological Oncology|November 24, 2016
First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective studyGodelieve Meunier, Loic Ysebaert, Phi Linh Nguyen-Thi, et al.
Bone Marrow Transplantation|March 4, 2021
Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trialBenoit Tessoulin, David Chiron, Catherine Thieblemont, et al.
The Lancet. Haematology|July 13, 2019
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 studyFranck Morschhauser, Steven Le Gouill, Pierre Feugier, et al.
Cancer|March 23, 2019
Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional studyNicolas Mounier, Sabine Anthony, Raphaël Busson, et al.
Bulletin Du Cancer|February 19, 2017
[Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment]Sabine Anthony, Pierre Hebel, André Garrel, et al.
Cytometry. Part B, Clinical Cytometry|October 7, 2011
Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS studyFrançoise Durrieu, Franck Geneviève, Christine Arnoulet, et al.
Haematologica|March 17, 2018
Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemiaPierre Feugier, Thérèse Aurran, Béatrice Mahé, et al.
The Lancet. Haematology|December 22, 2015
Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trialsMaja V Maraldo, Francesco Giusti, Ivan R Vogelius, et al.
Pageof 17

Showing results (81-90 of 164) with videos related to

Sort By:
Pageof 17
Blood Cancer Journal|August 13, 2025
Genomic and immunogenomic profiling of extramedullary acute myeloid leukemia reveals actionable clonal branching and frequent immune editingClément Collignon, Tucker Hansen, Colin Hercus, et al.
American Journal of Hematology|October 22, 2017
Characteristics of chronic lymphocytic leukemia patients achieving 5+ years of remission after FC-based first-line treatment: Retrospective observations from the FILO groupYann Guillermin, Charles Herbaux, Fabien Subtil, et al.
Hematological Oncology|November 24, 2016
First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective studyGodelieve Meunier, Loic Ysebaert, Phi Linh Nguyen-Thi, et al.
Bone Marrow Transplantation|March 4, 2021
Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trialBenoit Tessoulin, David Chiron, Catherine Thieblemont, et al.
The Lancet. Haematology|July 13, 2019
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 studyFranck Morschhauser, Steven Le Gouill, Pierre Feugier, et al.
Cancer|March 23, 2019
Long-term fatigue in survivors of non-Hodgkin lymphoma: The Lymphoma Study Association SIMONAL cross-sectional studyNicolas Mounier, Sabine Anthony, Raphaël Busson, et al.
Bulletin Du Cancer|February 19, 2017
[Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment]Sabine Anthony, Pierre Hebel, André Garrel, et al.
Cytometry. Part B, Clinical Cytometry|October 7, 2011
Normal levels of peripheral CD19(+) CD5(+) CLL-like cells: toward a defined threshold for CLL follow-up -- a GEIL-GOELAMS studyFrançoise Durrieu, Franck Geneviève, Christine Arnoulet, et al.
Haematologica|March 17, 2018
Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemiaPierre Feugier, Thérèse Aurran, Béatrice Mahé, et al.
The Lancet. Haematology|December 22, 2015
Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trialsMaja V Maraldo, Francesco Giusti, Ivan R Vogelius, et al.
Pageof 17